M
Mary Price
Researcher at Harvard University
Publications - 43
Citations - 1626
Mary Price is an academic researcher from Harvard University. The author has contributed to research in topics: Medicare Advantage & Population. The author has an hindex of 17, co-authored 35 publications receiving 1460 citations. Previous affiliations of Mary Price include Kaiser Permanente.
Papers
More filters
Journal ArticleDOI
Unintended Consequences of Caps on Medicare Drug Benefits
John Hsu,Mary Price,Jie Huang,Richard J. Brand,Vicki Fung,Rita Hui,Bruce Fireman,Joseph P. Newhouse,Joseph V. Selby +8 more
TL;DR: In patients with chronic disease, the cap on drug benefits was associated with poorer adherence to drug therapy and poorer control of blood pressure, lipid levels, and glucose levels.
Journal ArticleDOI
Validation of an algorithm for categorizing the severity of hospital emergency department visits.
Dustin W. Ballard,Mary Price,Vicki Fung,Richard J. Brand,Mary E. Reed,Bruce Fireman,Joseph P. Newhouse,Joseph V. Selby,John Hsu +8 more
TL;DR: The evidence presented supports the validity of the NYU ED visit severity algorithm for differentiating ED visits based on need for hospitalization and/or mortality risk; therefore, it can contribute to evidence-based policies aimed at reducing the use of the ED for nonemergencies.
Journal ArticleDOI
How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment
TL;DR: It is found that changes to payment rates for chemotherapy drugs administered on an outpatient basis actually increased the likelihood that lung cancer patients received chemotherapy, and the type of chemotherapy agents administered changed.
Journal ArticleDOI
Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
John Hsu,Vicki Fung,Mary Price,Jie Huang,Richard J. Brand,Rita Hui,Bruce Fireman,Joseph P. Newhouse +7 more
TL;DR: Beneficiaries in this Medicare Advantage plan have limited knowledge of Part D cost sharing and often report behavioral responses to drug costs, associated with fewer reports of cost responses overall, but more reports of financial burden.
Journal ArticleDOI
Steps To Reduce Favorable Risk Selection In Medicare Advantage Largely Succeeded, Boding Well For Health Insurance Exchanges
TL;DR: Differences in predicted spending between those switching from traditional Medicare to Medicare Advantage relative to those who remained in traditional Medicare markedly narrowed, as did adjusted mortality rates.